[Weak opioids].

Area of Science:

• Oncology
• Pharmacology
• Pain Management

Background:

• Weak opioids are utilized for managing moderate to severe chronic pain in cancer patients.
• Codeine is designated by the World Health Organization (WHO) as a second-step analgesic for cancer pain.
• The WHO cancer pain relief program utilizes codeine as a representative weak opioid analgesic.

Purpose of the Study:

• To review the efficacy and dosage of codeine as a weak opioid for cancer pain.
• To discuss the clinical ceiling effect and side effect management of codeine.
• To provide an overview of codeine's role in the WHO analgesic ladder for cancer pain.

Main Methods:

• Literature review on codeine's use in cancer pain management.
• Analysis of reported effective dosages and clinical ceiling effects.
• Examination of codeine's side effect profile and management strategies.

Main Results:

• Codeine demonstrates analgesic effects at oral doses of 20 mg or higher.
• The clinical ceiling effect for codeine appears to be between 200-300 mg/day, differing from some textbook recommendations of 600 mg/day.
• Codeine shares side effect profiles with morphine, necessitating simultaneous administration of supportive medications.

Conclusions:

• Codeine is an effective weak opioid for moderate to severe cancer pain, particularly within the WHO's second-step analgesic guidelines.
• Understanding codeine's effective dosage range and clinical ceiling is crucial for optimal pain management.
• Proactive management of codeine's side effects, similar to morphine, is essential for patient safety and treatment adherence.